These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19623257)

  • 1. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli.
    Chowdhury DR; Angov E; Kariuki T; Kumar N
    PLoS One; 2009 Jul; 4(7):e6352. PubMed ID: 19623257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding.
    Kumar R; Angov E; Kumar N
    Infect Immun; 2014 Apr; 82(4):1453-9. PubMed ID: 24421036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.
    Datta D; Bansal GP; Gerloff DL; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2017 Jan; 35(2):264-272. PubMed ID: 27912985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion to Tetrahymena thermophila granule lattice protein 1 confers solubility to sexual stage malaria antigens in Escherichia coli.
    Agrawal A; Bisharyan Y; Papoyan A; Bednenko J; Cardarelli J; Yao M; Clark T; Berkmen M; Ke N; Colussi P
    Protein Expr Purif; 2019 Jan; 153():7-17. PubMed ID: 30081196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
    Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice.
    Outchkourov NS; Roeffen W; Kaan A; Jansen J; Luty A; Schuiffel D; van Gemert GJ; van de Vegte-Bolmer M; Sauerwein RW; Stunnenberg HG
    Proc Natl Acad Sci U S A; 2008 Mar; 105(11):4301-5. PubMed ID: 18332422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.
    Theisen M; Jore MM; Sauerwein R
    Expert Rev Vaccines; 2017 Apr; 16(4):329-336. PubMed ID: 28043178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based
    Singh SK; Plieskatt J; Chourasia BK; Fabra-García A; Garcia-Senosiain A; Singh V; Bengtsson KL; Reimer JM; Sauerwein R; Jore MM; Theisen M
    Front Immunol; 2020; 11():606266. PubMed ID: 33505395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques.
    Datta D; Bansal GP; Grasperge B; Martin DS; Philipp M; Gerloff D; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2017 Dec; 35(50):7049-7056. PubMed ID: 29132995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants.
    Roeffen W; Theisen M; van de Vegte-Bolmer M; van Gemert G; Arens T; Andersen G; Christiansen M; Sevargave L; Singh SK; Kaviraj S; Sauerwein R
    Malar J; 2015 Nov; 14():443. PubMed ID: 26552428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Plasmodium falciparum transmission reducing immunity among primary school children in a malaria moderate transmission region in Zimbabwe.
    Paul NH; Vengesai A; Mduluza T; Chipeta J; Midzi N; Bansal GP; Kumar N
    Acta Trop; 2016 Nov; 163():103-8. PubMed ID: 27491342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmodium falciparum: heterologous synthesis of the transmission-blocking vaccine candidate Pfs48/45 in recombinant vaccinia virus-infected cells.
    Milek RL; DeVries AA; Roeffen WF; Stunnenberg H; Rottier PJ; Konings RN
    Exp Parasitol; 1998 Oct; 90(2):165-74. PubMed ID: 9769246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.
    Mistarz UH; Singh SK; Nguyen TTTN; Roeffen W; Yang F; Lissau C; Madsen SM; Vrang A; Tiendrebeogo RW; Kana IH; Sauerwein RW; Theisen M; Rand KD
    Pharm Res; 2017 Sep; 34(9):1970-1983. PubMed ID: 28646324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial.
    Alkema M; Smit MJ; Marin-Mogollon C; Totté K; Teelen K; van Gemert GJ; van de Vegte-Bolmer M; Mordmüller BG; Reimer JM; Lövgren-Bengtsson KL; Sauerwein RW; Bousema T; Plieskatt J; Theisen M; Jore MM; McCall MBB
    BMC Med; 2024 Apr; 22(1):170. PubMed ID: 38649867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations.
    Coban C; Philipp MT; Purcell JE; Keister DB; Okulate M; Martin DS; Kumar N
    Infect Immun; 2004 Jan; 72(1):253-9. PubMed ID: 14688103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons.
    Kumar R; Nyakundi R; Kariuki T; Ozwara H; Nyamongo O; Mlambo G; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2013 Jun; 31(31):3140-7. PubMed ID: 23684840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of full-length P. vivax rPvs48/45 protein formulations in BALB/c mice.
    Arévalo-Herrera M; Miura K; Solano E; Sebastián Ramírez J; Long CA; Corradin G; Herrera S
    Vaccine; 2022 Jan; 40(1):133-140. PubMed ID: 34802791
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Singh SK; Thrane S; Chourasia BK; Teelen K; Graumans W; Stoter R; van Gemert GJ; van de Vegte-Bolmer MG; Nielsen MA; Salanti A; Sander AF; Sauerwein RW; Jore MM; Theisen M
    Front Immunol; 2019; 10():1256. PubMed ID: 31231386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Plant-Produced in vivo deglycosylated full-length Pfs48/45 as a Transmission-Blocking Vaccine Candidate against malaria.
    Mamedov T; Cicek K; Miura K; Gulec B; Akinci E; Mammadova G; Hasanova G
    Sci Rep; 2019 Jul; 9(1):9868. PubMed ID: 31285498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.